A RECENT global study found significant improvements in health-related quality of life (HQoL) among individuals with Hepatitis C (HCV) treated with direct-acting antivirals (DAAs) under a minimal monitoring (MINMON) approach. The study, part of the ACTG A5360 trial, assessed the feasibility and impact of simplified treatment protocols across multiple countries, including the USA, Brazil, South Africa, Thailand, and Uganda.
With a focus on enhancing HCV treatment accessibility, the trial evaluated changes in HQoL using the EQ-5D-3L index and Visual Analog Scale (VAS) scores at baseline, Week 48, and Week 72. Among the 394 participants, the data revealed substantial improvements in HQoL, particularly for patients in Brazil and Thailand. However, participants in the USA did not show similar benefits, indicating geographical variability in treatment outcomes.
Factors contributing to the largest improvements included cirrhosis at baseline and non-problematic substance use. Interestingly, high rates of anxiety and depression were reported across participants, with noticeable decreases only in Brazil, highlighting the need for integrated mental health support as part of HCV treatment.
The findings underscore the effectiveness of DAAs in improving HQoL for individuals with HCV, especially those with advanced liver disease. However, they also emphasize the importance of continued mental health support, particularly for patients dealing with substance use and depression post-treatment.
For healthcare professionals, these results suggest that while DAAs are highly effective, a holistic approach addressing both physical and mental health needs is crucial for maximizing patient outcomes in HCV treatment.
Reference: Torres TS et al. Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life. Qual Life Res. 2025. doi: 10.1007/s11136-025-03922-1. [Online ahead of print].
Anaya Malik | AMJ
